,

Rev Esp Quimioter 2021;34(Suppl.1):26-28

Dalbavancin

JOSÉ BARBERÁN, ALICIA DE LA CUERDA, LOURDES CRISTINA BARBERÁN

Published: 30 September 2021

http://www.doi.org/10.37201/req/s01.07.2021

Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. The unusually long terminal half-life ranging from 149 to 250 hours in human subjects, allows a weekly dose. Currently is indicated in acute bacterial skin and skin structure infections (ABSSSIs), but in real-life clinical practice it has already been used successfully and safely in other infections, especially as consolidation therapy.

Rev Esp Quimioter 2021; 34(Suppl. 1):26-28 [Full-text PDF]


/por
Rev Esp Quimioter 2021;34(Suppl.1):22-25Rev Esp Quimioter 2021;34(Suppl.1):29-31